Stenting And Thrombectomy Systems Fuel Neuro Device Market Growth

The US market for neurointerventional systems is expected to exhibit healthy growth over the next five years, with a compound annual rate of 6.5%, from approximately $617.1 million in 2013 to an estimated $846.2 million in 2018, according to a report from Medtech Insight. Gains in this segment will be supported by anticipated strong advances in (distally protected) carotid stenting (CAS) and cerebral thrombectomy systems revenues, which combined contributed an estimated 41.2% of the neurointerventional market in 2013. Gains in the CAS market are based on positive results of the pivotal study CREST, which supported FDA approval of the CAS techniques for standard surgical-risk patients. Strong advances (albeit from a low base) are also expected in the cerebral thrombectomy segment, based on the enthusiastic adoption of second-generation stent-based clot retrieval systems (such as Medtronic Minimally Invasive Therapies’s Solitaire FR and Stryker Corp.'s TREVO Pro series) for acute ischemic stroke.